Open AccessResponse to ibrutinib in chronic lymphocytic leukemia improves in quality with time
Author(s) -
Molica Stefano,
Carillio Guido,
Battaglia Caterina
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.749
Subject(s) - ibrutinib , medicine , chronic lymphocytic leukemia , cancer research , leukemia , oncology , pharmacology
Key Clinical Message Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first‐in‐class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long‐term ibrutinib promotes a high response rate that improves in quality with time.